GlassScriptPhysician profile
Kendra Pearl Watts
NPI 1114428034
$3,044.67
in general payments reported to CMS, 2019-2025
24 companies · $595 in 2025
The $595 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $367 · 2022: $659 · 2023: $700 · 2024: $724 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $600.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $437.83 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $404.22 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $262.50 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $249.95 | 2023-2025 | Rexulti |
| Abbvie INC. | $147.43 | 2021-2025 | |
| Lilly USA, LLC | $116.14 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Mylan Specialty L.P. | $101.69 | 2021-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $97.09 | 2021-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $92.57 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.47 | 2021-2024 | Jardiance |
| Pfizer INC. | $89.95 | 2021-2024 | |
| Axsome Therapeutics, INC. | $56.52 | 2025 | Auvelity |
| Ardelyx, INC. | $46.32 | 2024 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.61 | 2025 | Caplyta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $32.44 | 2023-2024 | Nuzyra |
| Exact Sciences Corporation | $29.52 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $28.58 | 2021-2024 | Veozah |
| Viatris Specialty LLC | $24.29 | 2025 | Yupelri |
| Abbott Laboratories | $24.04 | 2023 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $23.22 | 2025 | Trintellix |
| Organon LLC | $19.80 | 2023 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.57 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.